Oncopeptides AB

Oncopeptides AB
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

Oncopeptides is a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company uses its proprietary peptide-drug conjugate (PDC) platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. The first drug coming from PDC platform, PEPAXTO®(melphalan flufenamide), has been launched in the U.S., for the treatment of adult patients with relapsed or refractory multiple myeloma. Melphalan flufenamide is evaluated in a comprehensive clinical study program including the global phase 3 studies OCEAN and LIGHTHOUSE. Oncopeptides is developing several new compounds based on the PDC platform. The first one is expected to enter into clinical development in 2021.Oncopeptides has approximately 300 coworkers. The global Headquarters is based in Stockholm, Sweden and the U.S. Headquarters is situated in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. More information is available on www.oncopeptides.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Oncopeptides announces leadership changes: Jakob Lindberg assumes a new role as CSO, and Marty J Duvall is appointed CEO

Tue, Jun 30, 2020 17:45 CET

STOCKHOLM — June 30, 2020 — Oncopeptides AB (publ) (“Oncopeptides”) (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. Jakob Lindberg assumes the role as Chief Scientific Officer, CSO, replacing MD Christian Jacques who has held the position as CSO since 2018. Christian will continue as a Senior Advisor. .Marty J Duvall brings extensive global commercialization skills from executive leadership roles in pharma and

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Oncopeptides announces leadership changes: Jakob Lindberg assumes a new role as CSO, and Marty J Duvall is appointed CEO

Subscribe

Media